Dementia-Pipeline Review, H1 2015

Dementia-Pipeline Review, H1 2015

  • Products Id :- GMDHC6025IDB
  • |
  • Pages: 166
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Dementia-Pipeline Review, H1 2015


Global Markets Direct's, 'Dementia-Pipeline Review, H1 2015', provides an overview of the Dementia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Dementia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dementia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Dementia

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Dementia and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Dementia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Dementia pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Dementia

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Dementia pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Dementia Overview 8

Therapeutics Development 9

Pipeline Products for Dementia-Overview 9

Pipeline Products for Dementia-Comparative Analysis 10

Dementia-Therapeutics under Development by Companies 11

Dementia-Therapeutics under Investigation by Universities/Institutes 14

Dementia-Pipeline Products Glance 16

Late Stage Products 16

Clinical Stage Products 17

Early Stage Products 18

Dementia-Products under Development by Companies 19

Dementia-Products under Investigation by Universities/Institutes 22

Dementia-Companies Involved in Therapeutics Development 23

Actinogen Limited 23

Alector LLC 24

AlzProtect SAS 25

BioArctic Neuroscience AB 26

Biogen Idec Inc. 27

Biotie Therapies Corp. 28

Bristol-Myers Squibb Company 29

Chase Pharmaceuticals Corporation 30

Chronos Therapeutics Limited 31

Daewoong Pharmaceutical Co., Ltd. 32

Echo Pharmaceuticals B.V. 33

Eisai Co., Ltd. 34

FORUM Pharmaceuticals Inc. 35

Hyundai Pharmaceutical Co., Ltd. 36

Ildong Pharmaceutical Co., Ltd. 37

IMMD Inc. 38

ImStar Therapeutics Inc. 39

Integrative Research Laboratories Sweden AB 40

Intellect Neurosciences, Inc. 41

Intra-Cellular Therapies, Inc. 42

Neurimmune Holding AG 43

Oryzon Genomics S.A. 44

Otsuka Holdings Co., Ltd. 45

Pacific Northwest Biotechnology, LLC 46

ProteoTech, Inc. 47

SK Chemicals Co., Ltd. 48

Stelic Institute & Co. 49

Sumitomo Dainippon Pharma Co., Ltd. 50

Sylentis S.A. 51

TauRx Therapeutics Ltd. 52

Tautatis Incorporated 53

Varinel, Inc. 54

WhanIn Pharmaceutical Co., Ltd. 55

Dementia-Therapeutics Assessment 56

Assessment by Monotherapy Products 56

Assessment by Target 57

Assessment by Mechanism of Action 60

Assessment by Route of Administration 62

Assessment by Molecule Type 64

Drug Profiles 66

Antisense Oligonucleotide to Inhibit microRNA for Neurology-Drug Profile 66

aripiprazole-Drug Profile 67

AVCRI-104P3-Drug Profile 70

AZP-2006-Drug Profile 71

brexpiprazole-Drug Profile 73

choline alfoscerate SR-Drug Profile 75

CPC-201-Drug Profile 76

CPC-252-Drug Profile 77

dehydroevodiamine hydrochloride-Drug Profile 78

dronabinol-Drug Profile 79

Drugs for Dementia-Drug Profile 81

Drugs to Agonize c-MET for Dementia-Drug Profile 82

Drugs to Inhibit Matrix Metalloproteinase for Dementia and Cognitive Impairment-Drug Profile 83

DWJ-1365-Drug Profile 84

E-2609-Drug Profile 85

encenicline hydrochloride-Drug Profile 86

FRM-0334-Drug Profile 89

GIBH-130-Drug Profile 91

gugulipid-Drug Profile 92

IIPP-1-Drug Profile 93

IMD-4482-Drug Profile 94

IPN-007-Drug Profile 95

IRL-752-Drug Profile 96

ITI-007-Drug Profile 97

KR-12-Drug Profile 99

Monoclonal Antibodies for Dementia and Alzheimer's Disease-Drug Profile 100

Monoclonal Antibodies to Inhibit Tau for CNS Disorders-Drug Profile 101

NAT-Drug Profile 102

NI-205-Drug Profile 103

NI-308-Drug Profile 104

NNC-269100-Drug Profile 105

OG-635-Drug Profile 106

PD-0805-Drug Profile 107

PD-61W3-Drug Profile 108

PD-61W3 Backup-Drug Profile 109

Peptide to Inhibit BACE for Cerebropathy and Dementia-Drug Profile 110

PST-900-Drug Profile 111

RDC-5-Drug Profile 112

RNAi Oligonucleotide for Cerebral Ischemia and Dementia-Drug Profile 114

SID-111-Drug Profile 115

Small Molecule to Activate LPL for CNS and Metabolic Disorders-Drug Profile 116

Small Molecule to Inhibit Glycogene 5 for Dementia-Drug Profile 117

Small Molecules for Ophthalmology and CNS Disorders-Drug Profile 118

Small Molecules to Inhibit LSD-1 And MAO-B for Neurodegenerative Diseases-Drug Profile 119

Small Molecules to Inhibit TANA for ALS, Dementia and Alzheimer's Disease-Drug Profile 120

SYN-120-Drug Profile 121

Synthetic Peptides for Neurological Disorders-Drug Profile 122

TAK-070-Drug Profile 123

TauC-3-Drug Profile 124

TPI-287-Drug Profile 125

TRx-0237-Drug Profile 127

TTT-3002-Drug Profile 129

UE-2343-Drug Profile 130

VAR-10100-Drug Profile 131

WIB-1001C-Drug Profile 132

zonisamide-Drug Profile 133

Dementia-Recent Pipeline Updates 134

Dementia-Dormant Projects 150

Dementia-Discontinued Products 152

Dementia-Product Development Milestones 153

Featured News & Press Releases 153

Appendix 161

Methodology 161

Coverage 161

Secondary Research 161

Primary Research 161

Expert Panel Validation 161

Contact Us 162

Disclaimer 162

List of Tables

Number of Products under Development for Dementia, H1 2015 13

Number of Products under Development for Dementia-Comparative Analysis, H1 2015 14

Number of Products under Development by Companies, H1 2015 16

Number of Products under Development by Companies, H1 2015 (Contd..1) 17

Number of Products under Investigation by Universities/Institutes, H1 2015 19

Comparative Analysis by Late Stage Development, H1 2015 20

Comparative Analysis by Clinical Stage Development, H1 2015 21

Comparative Analysis by Early Stage Development, H1 2015 22

Products under Development by Companies, H1 2015 23

Products under Development by Companies, H1 2015 (Contd..1) 24

Products under Development by Companies, H1 2015 (Contd..2) 25

Products under Investigation by Universities/Institutes, H1 2015 26

Dementia-Pipeline by Actinogen Limited, H1 2015 27

Dementia-Pipeline by Alector LLC, H1 2015 28

Dementia-Pipeline by AlzProtect SAS, H1 2015 29

Dementia-Pipeline by BioArctic Neuroscience AB, H1 2015 30

Dementia-Pipeline by Biogen Idec Inc., H1 2015 31

Dementia-Pipeline by Biotie Therapies Corp., H1 2015 32

Dementia-Pipeline by Bristol-Myers Squibb Company, H1 2015 33

Dementia-Pipeline by Chase Pharmaceuticals Corporation, H1 2015 34

Dementia-Pipeline by Chronos Therapeutics Limited, H1 2015 35

Dementia-Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2015 36

Dementia-Pipeline by Echo Pharmaceuticals B.V., H1 2015 37

Dementia-Pipeline by Eisai Co., Ltd., H1 2015 38

Dementia-Pipeline by FORUM Pharmaceuticals Inc., H1 2015 39

Dementia-Pipeline by Hyundai Pharmaceutical Co., Ltd., H1 2015 40

Dementia-Pipeline by Ildong Pharmaceutical Co., Ltd., H1 2015 41

Dementia-Pipeline by IMMD Inc., H1 2015 42

Dementia-Pipeline by ImStar Therapeutics Inc., H1 2015 43

Dementia-Pipeline by Integrative Research Laboratories Sweden AB, H1 2015 44

Dementia-Pipeline by Intellect Neurosciences, Inc., H1 2015 45

Dementia-Pipeline by Intra-Cellular Therapies, Inc., H1 2015 46

Dementia-Pipeline by Neurimmune Holding AG, H1 2015 47

Dementia-Pipeline by Oryzon Genomics S.A., H1 2015 48

Dementia-Pipeline by Otsuka Holdings Co., Ltd., H1 2015 49

Dementia-Pipeline by Pacific Northwest Biotechnology, LLC, H1 2015 50

Dementia-Pipeline by ProteoTech, Inc., H1 2015 51

Dementia-Pipeline by SK Chemicals Co., Ltd., H1 2015 52

Dementia-Pipeline by Stelic Institute & Co., H1 2015 53

Dementia-Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2015 54

Dementia-Pipeline by Sylentis S.A., H1 2015 55

Dementia-Pipeline by TauRx Therapeutics Ltd., H1 2015 56

Dementia-Pipeline by Tautatis Incorporated, H1 2015 57

Dementia-Pipeline by Varinel, Inc., H1 2015 58

Dementia-Pipeline by WhanIn Pharmaceutical Co., Ltd., H1 2015 59

Assessment by Monotherapy Products, H1 2015 60

Number of Products by Stage and Target, H1 2015 62

Number of Products by Stage and Mechanism of Action, H1 2015 65

Number of Products by Stage and Route of Administration, H1 2015 67

Number of Products by Stage and Molecule Type, H1 2015 69

Dementia Therapeutics-Recent Pipeline Updates, H1 2015 138

Dementia-Dormant Projects, H1 2015 154

Dementia-Discontinued Products, H1 2015 156

List of Figures

Number of Products under Development for Dementia, H1 2015 13

Number of Products under Development for Dementia-Comparative Analysis, H1 2015 14

Number of Products under Development by Companies, H1 2015 15

Number of Products under Investigation by Universities/Institutes, H1 2015 18

Comparative Analysis by Clinical Stage Development, H1 2015 21

Comparative Analysis by Early Stage Products, H1 2015 22

Assessment by Monotherapy Products, H1 2015 60

Number of Products by Top 10 Targets, H1 2015 61

Number of Products by Stage and Top 10 Targets, H1 2015 61

Number of Products by Top 10 Mechanism of Actions, H1 2015 64

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 64

Number of Products by Top 10 Routes of Administration, H1 2015 66

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 67

Number of Products by Top 10 Molecule Types, H1 2015 68

Number of Products by Stage and Top 10 Molecule Types, H1 2015 69

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Actinogen Limited

Alector LLC

AlzProtect SAS

BioArctic Neuroscience AB

Biogen Idec Inc.

Biotie Therapies Corp.

Bristol-Myers Squibb Company

Chase Pharmaceuticals Corporation

Chronos Therapeutics Limited

Daewoong Pharmaceutical Co., Ltd.

Echo Pharmaceuticals B.V.

Eisai Co., Ltd.

FORUM Pharmaceuticals Inc.

Hyundai Pharmaceutical Co., Ltd.

Ildong Pharmaceutical Co., Ltd.


ImStar Therapeutics Inc.

Integrative Research Laboratories Sweden AB

Intellect Neurosciences, Inc.

Intra-Cellular Therapies, Inc.

Neurimmune Holding AG

Oryzon Genomics S.A.

Otsuka Holdings Co., Ltd.

Pacific Northwest Biotechnology, LLC

ProteoTech, Inc.

SK Chemicals Co., Ltd.

Stelic Institute & Co.

Sumitomo Dainippon Pharma Co., Ltd.

Sylentis S.A.

TauRx Therapeutics Ltd.

Tautatis Incorporated

Varinel, Inc.

WhanIn Pharmaceutical Co., Ltd.

Dementia Therapeutic Products under Development, Key Players in Dementia Therapeutics, Dementia Pipeline Overview, Dementia Pipeline, Dementia Pipeline Assessment

select a license

Single User License
USD 2000 INR 129780
Site License
USD 4000 INR 259560
Corporate User License
USD 6000 INR 389340



The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...

Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]